Loading
Instead of starting everyone on the full dose and cutting back after side effects, start lower and increase in patients who tolerate it. This keeps more people on treatment and is how blood-pressure drugs are given.
Randomised comparisons of standard full-dose start versus a step-up schedule (starting at 50-70 percent of label dose, escalating at cycle 2-3 in the absence of toxicity) for oral agents with high early discontinuation rates (some PARP inhibitors, multi-kinase inhibitors, CDK4/6 inhibitors, PI3K/AKT inhibitors). Niraparib's individualised starting dose by weight and platelet count is a precedent that improved tolerability without loss of efficacy.
Shares Abemaciclib, Wrong doses, Toxicity and quality of life are undervalued.
Shares Abemaciclib, CDK4/6 inhibitors.
Shares Niraparib, PARP inhibitors.
Shares Niraparib, PARP inhibitors.
Shares Abemaciclib, CDK4/6 inhibitors, Wrong doses.
Shares Abemaciclib, CDK4/6 inhibitors.
Shares Niraparib, PARP inhibitors.
Shares Wrong doses, Toxicity and quality of life are undervalued.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/